AnaptysBio Inc diskutieren
AnaptysBio Inc
WKN: A2AJ8C / Symbol: ANAB / Name: AnaptysBio / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
38,00 €
-2,06 %
Der Beitrag wird untersucht
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $25.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at JPMorgan Chase & Co. from $36.00 to $42.00. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at Guggenheim.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $52.00 to $54.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $54.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $38.00 price target on the stock, up previously from $22.00.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $80.00. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Wedbush from $40.00 to $45.00. They now have an "outperform" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at HC Wainwright from $38.00 to $59.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at Wedbush. They now have an "outperform" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Wells Fargo & Company from $51.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target raised by analysts at Guggenheim from $90.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush.
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $59.00 to $52.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat
Neueste Beiträge
HC_Wainwright in Biocryst Pharmaceuticals diskutieren